4,901 trials
Contraception
Primary: Mean Maximum Concentration (Cmax) of EE Incl. Bioequivalence (BE) Evaluation — 39.6; 41.9 pg/mL
Skin Manifestations
Primary: Number of Participants Who Were a Success With Regard to Worst Post-baseline Tolerability Assessment Scores in Each Category of the Tolerability Assessments (Erythema…
Contraception
Primary: Mean Maximum Concentration (Cmax) of EE Incl. Bioequivalence (BE) Evaluation — 58.5; 61.6 pg/mL
Skin Manifestations
Primary: Number of Participants Who Were a Success With Regard to Worst Post-baseline Tolerability Assessment Scores in Each Category of the Tolerability Assessments (Erythema…
Healthy
Primary: Maximum Plasma Concentration (Cmax) — 2.407; 2.122 ng/mL
Cancer
Primary: Maximum Tolerated Dose (MTD) of Ixabepilone — 25 mg/d
Depressive Disorder
Primary: AUC_ss — 672.9221; 645.5407 ng.h/ml
Leukemia
Primary: Number of Participants Who Died, Experienced Other Serious Adverse Events (SAEs), Adverse Events (AEs) and AEs Leading to Study Drug Discontinuation. — 3; 2; 1; 1…
Primary Hypercholesterolemia · Mixed Hyperlipidemia
Primary: Cutaneous Bleeding Time (BT) — 478; 389 Seconds
Depressive Disorder
Primary: Area Under the Curve_steady-state — 996.2436; 1038.5812 ng/h/ml
Non-small Cell Lung Cancer (NSCLC)
Primary: Number of Participants With Dose-limiting Toxicity (DLT) — 0; 1 Participants
Rotavirus Gastroenteritis
Primary: Number of Participants With Serious Adverse Events — 0; 0; 0; 0 Participants
Herpes Zoster
Primary: Number of Participants With a Negative VZV Skin Test at Baseline (Part A) — 23 Participants
Rheumatoid Arthritis
Primary: Synovial Blood Flow — 9.48; 10.55; 8.31; 9.78 pixel count
Diabetes Mellitus, Type 2
Primary: AUC0-t of Rosiglitazone Maleate — 1731.22; 1770.93 ng per hour per ml (ng.h/ml)